Venous thromboembolism in ovarian cancer

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Objective.: To determine the incidence, time-course, and risk factors associated with the development of thromboembolism (VTE) in a population-based study of women with ovarian cancer. Methods.: Using the California Cancer Registry, cases diagnosed with ovarian cancer for a 6-year period were identified. These cases were linked with the California Patient Discharge Data Set to determine the incidence of VTE. Proportional hazards modeling was performed to analyze the strength of specified risk factors to predict development of VTE or death within 2 years. Results.: Among 13,031 cases with ovarian cancer, 5.2% were diagnosed with a VTE event within 24 months after diagnosis. The cumulative incidence varied from 1.4% among women with local stage disease to 6.7% among women with advanced disease. The person-time incidence rate of VTE decreased over time, with the highest rate noted during the first 3 months. In a multivariate model, significant risk factors for VTE included advancing age, increasing number of chronic comorbid conditions, more advanced cancer stage, invasive histology, and absence of any major surgery. For all stages of cancer, development of VTE within 2 years was a significant risk factor for decreased survival, and the magnitude of the risk was greatest among the cases diagnosed with localized disease (HR 4.7, 95% CI: 2.3-9.5). Conclusions.: VTE occurred in a significant proportion of ovarian cancer patients and adversely impacted survival, particularly among cases with local or regional stage cancer.

Original languageEnglish (US)
Pages (from-to)784-790
Number of pages7
JournalGynecologic Oncology
Volume105
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Venous Thromboembolism
Ovarian Neoplasms
Incidence
Neoplasms
Survival
Patient Discharge
Thromboembolism
Registries
Histology
Population

Keywords

  • Deep vein thrombosis
  • Ovarian cancer
  • Ovarian carcinoma
  • Pulmonary embolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Venous thromboembolism in ovarian cancer. / Rodriguez, Anne O.; Wun, Theodore; Chew, Helen K; Zhou, Hong; Harvey, Danielle J; White, Richard H.

In: Gynecologic Oncology, Vol. 105, No. 3, 06.2007, p. 784-790.

Research output: Contribution to journalArticle

@article{f7ae7e5e1aae4fb0bc2514751a804b59,
title = "Venous thromboembolism in ovarian cancer",
abstract = "Objective.: To determine the incidence, time-course, and risk factors associated with the development of thromboembolism (VTE) in a population-based study of women with ovarian cancer. Methods.: Using the California Cancer Registry, cases diagnosed with ovarian cancer for a 6-year period were identified. These cases were linked with the California Patient Discharge Data Set to determine the incidence of VTE. Proportional hazards modeling was performed to analyze the strength of specified risk factors to predict development of VTE or death within 2 years. Results.: Among 13,031 cases with ovarian cancer, 5.2{\%} were diagnosed with a VTE event within 24 months after diagnosis. The cumulative incidence varied from 1.4{\%} among women with local stage disease to 6.7{\%} among women with advanced disease. The person-time incidence rate of VTE decreased over time, with the highest rate noted during the first 3 months. In a multivariate model, significant risk factors for VTE included advancing age, increasing number of chronic comorbid conditions, more advanced cancer stage, invasive histology, and absence of any major surgery. For all stages of cancer, development of VTE within 2 years was a significant risk factor for decreased survival, and the magnitude of the risk was greatest among the cases diagnosed with localized disease (HR 4.7, 95{\%} CI: 2.3-9.5). Conclusions.: VTE occurred in a significant proportion of ovarian cancer patients and adversely impacted survival, particularly among cases with local or regional stage cancer.",
keywords = "Deep vein thrombosis, Ovarian cancer, Ovarian carcinoma, Pulmonary embolism, Venous thromboembolism",
author = "Rodriguez, {Anne O.} and Theodore Wun and Chew, {Helen K} and Hong Zhou and Harvey, {Danielle J} and White, {Richard H}",
year = "2007",
month = "6",
doi = "10.1016/j.ygyno.2007.02.024",
language = "English (US)",
volume = "105",
pages = "784--790",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Venous thromboembolism in ovarian cancer

AU - Rodriguez, Anne O.

AU - Wun, Theodore

AU - Chew, Helen K

AU - Zhou, Hong

AU - Harvey, Danielle J

AU - White, Richard H

PY - 2007/6

Y1 - 2007/6

N2 - Objective.: To determine the incidence, time-course, and risk factors associated with the development of thromboembolism (VTE) in a population-based study of women with ovarian cancer. Methods.: Using the California Cancer Registry, cases diagnosed with ovarian cancer for a 6-year period were identified. These cases were linked with the California Patient Discharge Data Set to determine the incidence of VTE. Proportional hazards modeling was performed to analyze the strength of specified risk factors to predict development of VTE or death within 2 years. Results.: Among 13,031 cases with ovarian cancer, 5.2% were diagnosed with a VTE event within 24 months after diagnosis. The cumulative incidence varied from 1.4% among women with local stage disease to 6.7% among women with advanced disease. The person-time incidence rate of VTE decreased over time, with the highest rate noted during the first 3 months. In a multivariate model, significant risk factors for VTE included advancing age, increasing number of chronic comorbid conditions, more advanced cancer stage, invasive histology, and absence of any major surgery. For all stages of cancer, development of VTE within 2 years was a significant risk factor for decreased survival, and the magnitude of the risk was greatest among the cases diagnosed with localized disease (HR 4.7, 95% CI: 2.3-9.5). Conclusions.: VTE occurred in a significant proportion of ovarian cancer patients and adversely impacted survival, particularly among cases with local or regional stage cancer.

AB - Objective.: To determine the incidence, time-course, and risk factors associated with the development of thromboembolism (VTE) in a population-based study of women with ovarian cancer. Methods.: Using the California Cancer Registry, cases diagnosed with ovarian cancer for a 6-year period were identified. These cases were linked with the California Patient Discharge Data Set to determine the incidence of VTE. Proportional hazards modeling was performed to analyze the strength of specified risk factors to predict development of VTE or death within 2 years. Results.: Among 13,031 cases with ovarian cancer, 5.2% were diagnosed with a VTE event within 24 months after diagnosis. The cumulative incidence varied from 1.4% among women with local stage disease to 6.7% among women with advanced disease. The person-time incidence rate of VTE decreased over time, with the highest rate noted during the first 3 months. In a multivariate model, significant risk factors for VTE included advancing age, increasing number of chronic comorbid conditions, more advanced cancer stage, invasive histology, and absence of any major surgery. For all stages of cancer, development of VTE within 2 years was a significant risk factor for decreased survival, and the magnitude of the risk was greatest among the cases diagnosed with localized disease (HR 4.7, 95% CI: 2.3-9.5). Conclusions.: VTE occurred in a significant proportion of ovarian cancer patients and adversely impacted survival, particularly among cases with local or regional stage cancer.

KW - Deep vein thrombosis

KW - Ovarian cancer

KW - Ovarian carcinoma

KW - Pulmonary embolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=34248389000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248389000&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.02.024

DO - 10.1016/j.ygyno.2007.02.024

M3 - Article

C2 - 17408726

AN - SCOPUS:34248389000

VL - 105

SP - 784

EP - 790

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -